OBJECTIVE: To determine whether polymorphic variations in the apolipoprotein E gene (APOE) are associated with increased risk of frontotemporal lobar degeneration (FTLD) when mutation in tau gene is absent. METHODS: The APOE gene was genotyped by polymerase chain reaction from DNA routinely extracted from blood or brain tissues. The APOE epsilon4 allele frequency in 198 patients with FTLD not associated with mutations in tau gene was compared with that of a control group of 756 normal individuals drawn from the same geographical region. Analyses were done according to clinical subtype or sex. RESULTS: The APOE epsilon4 allele frequency (19.4%) was increased (p = 0.01) in FTLD v the whole control group (14.1%), while the APOE epsilon2 allele frequency in FTLD (6.5%) was slightly lower than in controls (8.0%) (NS). The APOE epsilon4 allele frequency in men with FTLD (22.3%) was greater (p = 0.002) than in male controls (12.3%); the frequency in women (16.3%) was similar to that in female controls (14.8%) (NS). The APOE epsilon2 allele frequency in men with FTLD was 4.9% while in male controls it was 9.5% (p = 0.06), but there was no difference in women (7.5% v 7.9%, NS). Neither the APOE epsilon2 nor APOE epsilon4 allele frequency varied significantly between any of the clinical subtypes. CONCLUSIONS: In FTLD not associated with mutations in tau gene, possession of APOE epsilon4 allele in men roughly doubles the chances of developing disease, whereas this has no impact upon disease risk in women.
OBJECTIVE: To determine whether polymorphic variations in the apolipoprotein E gene (APOE) are associated with increased risk of frontotemporal lobar degeneration (FTLD) when mutation in tau gene is absent. METHODS: The APOE gene was genotyped by polymerase chain reaction from DNA routinely extracted from blood or brain tissues. The APOE epsilon4 allele frequency in 198 patients with FTLD not associated with mutations in tau gene was compared with that of a control group of 756 normal individuals drawn from the same geographical region. Analyses were done according to clinical subtype or sex. RESULTS: The APOE epsilon4 allele frequency (19.4%) was increased (p = 0.01) in FTLD v the whole control group (14.1%), while the APOE epsilon2 allele frequency in FTLD (6.5%) was slightly lower than in controls (8.0%) (NS). The APOE epsilon4 allele frequency in men with FTLD (22.3%) was greater (p = 0.002) than in male controls (12.3%); the frequency in women (16.3%) was similar to that in female controls (14.8%) (NS). The APOE epsilon2 allele frequency in men with FTLD was 4.9% while in male controls it was 9.5% (p = 0.06), but there was no difference in women (7.5% v 7.9%, NS). Neither the APOE epsilon2 nor APOE epsilon4 allele frequency varied significantly between any of the clinical subtypes. CONCLUSIONS: In FTLD not associated with mutations in tau gene, possession of APOE epsilon4 allele in men roughly doubles the chances of developing disease, whereas this has no impact upon disease risk in women.
Authors: S F Fabre; C Forsell; M Viitanen; M Sjögren; A Wallin; K Blennow; M Blomberg; C Andersen; L O Wahlund; L Lannfelt Journal: Exp Neurol Date: 2001-04 Impact factor: 5.330
Authors: S M Pickering-Brown; F Owen; A Isaacs; J Snowden; A Varma; D Neary; R Furlong; S E Daniel; N J Cairns; D M Mann Journal: Exp Neurol Date: 2000-06 Impact factor: 5.330
Authors: D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson Journal: Neurology Date: 1998-12 Impact factor: 9.910
Authors: M Ingelson; S F Fabre; L Lilius; C Andersen; M Viitanen; O Almkvist; L O Wahlund; L Lannfelt Journal: Neuroreport Date: 2001-04-17 Impact factor: 1.837
Authors: S M Pickering-Brown; A M T Richardson; J S Snowden; A M McDonagh; A Burns; W Braude; M Baker; W-K Liu; S-H Yen; J Hardy; M Hutton; Y Davies; D Allsop; D Craufurd; D Neary; D M A Mann Journal: Brain Date: 2002-04 Impact factor: 13.501
Authors: A Kowalska; T Asada; K Arima; C Kumakiri; W Kozubski; K Takahashi; T Tabira Journal: Dement Geriatr Cogn Disord Date: 2001 Nov-Dec Impact factor: 2.959
Authors: J Kálmán; A Juhász; K Majtényi; A Rimanóczy; K Jakab; G Gárdián; I Raskó; Z Janka Journal: Neurobiol Aging Date: 2000 Jul-Aug Impact factor: 4.673
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Raffaele Ferrari; Yunpeng Wang; Jana Vandrovcova; Sebastian Guelfi; Aree Witeolar; Celeste M Karch; Andrew J Schork; Chun C Fan; James B Brewer; Parastoo Momeni; Gerard D Schellenberg; William P Dillon; Leo P Sugrue; Christopher P Hess; Jennifer S Yokoyama; Luke W Bonham; Gil D Rabinovici; Bruce L Miller; Ole A Andreassen; Anders M Dale; John Hardy; Rahul S Desikan Journal: J Neurol Neurosurg Psychiatry Date: 2016-11-29 Impact factor: 10.154
Authors: Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2007-06-20 Impact factor: 17.088
Authors: Federica Agosta; Keith A Vossel; Bruce L Miller; Raffaella Migliaccio; Stephen J Bonasera; Massimo Filippi; Adam L Boxer; Anna Karydas; Katherine L Possin; Maria Luisa Gorno-Tempini Journal: Proc Natl Acad Sci U S A Date: 2009-01-22 Impact factor: 11.205